Author:
Wang Qiao,Peng Hongling,Qi Xiaorong,Wu Min,Zhao Xia
Abstract
AbstractAdvanced and recurrent gynecological cancers are associated with poor prognosis and lack of effective treatment. The developments of the molecular mechanisms on cancer progression provide insight into novel targeted therapies, which are emerging as groundbreaking and promising cancer treatment strategies. In gynecologic malignancies, potential therapeutic targeted agents include antiangiogenic agents, poly (ADP-ribose) polymerase (PARP) inhibitors, tumor-intrinsic signaling pathway inhibitors, selective estrogen receptor downregulators, and immune checkpoint inhibitors. In this article, we provide a comprehensive review of the clinical evidence of targeted agents in gynecological cancers and discuss the future implication.
Funder
National Major Scientific and Technological Project for significant new drugs development in China
Publisher
Springer Science and Business Media LLC
Reference436 articles.
1. Siegel, R., Miller, K. & Jemal, A. Cancer statistics, 2019. CA: Cancer J. Clin.69, 7–34 (2019).
2. Matulonis, U. A. et al. Ovarian cancer. Nat. Rev. Dis. Prim.2, 16061 (2016).
3. Jelovac, D. & Armstrong, D. K. Recent progress in the diagnosis and treatment of ovarian cancer. CA: Cancer J. Clin.61, 183–203 (2011).
4. Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer15, 668 (2015).
5. Bristow, R. E. et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol.72, 278–287 (1999).
Cited by
104 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献